Immunome Inc. (IMNM) — 10-Q Filings

10-Q Filings (6)

• Immunome Boosts Cash by $129M, Narrows Loss Amid R&D Surge — Nov 6, 2025 Risk: medium
  Immunome Inc. reported a significant increase in cash and cash equivalents to $272.6 million as of September 30, 2025, up from $143.4 million at December 31, 20
• Immunome's Q2 Net Loss Widens to $25.2M Amid R&D Surge — Aug 6, 2025 Risk: high
  Immunome Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for the thr
• Immunome Inc. Q1 2025 10-Q: Assets $87M, Liabilities $64M — May 12, 2025 Risk: medium
  Immunome Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $86.96 million and total liabilities of $64.46 million.
• Immunome Reports Q3 Loss, Details Equity Transactions — Nov 13, 2024 Risk: medium
  Immunome Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $43.3 million and total liabilities of $6.0 million
• Immunome Inc. Q2 2024 Update: Cash Position and Financing Activities — Aug 12, 2024 Risk: medium
  Immunome Inc. filed its 10-Q for the period ending June 30, 2024, reporting a cash balance of $43.3 million. The filing details various financing activities, in
• Immunome Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk:
  Immunome Inc. (IMNM) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Immunome Inc. reported financial results for the quarter ended March 31, 2024

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX